Kyowa Kirin
Kyowa Kirin Co., Ltd., a prominent biopharmaceutical company, is headquartered in Tokyo, Japan (JP). Founded in 1949, the company has established a strong presence in the global healthcare industry, focusing on innovative drug development in areas such as oncology, nephrology, and immunology. Kyowa Kirin is renowned for its unique biologics and small molecule therapies, which leverage advanced technologies to address unmet medical needs. The company has achieved significant milestones, including the successful launch of several key products that have positioned it as a leader in the biopharmaceutical sector. With a commitment to research and development, Kyowa Kirin continues to expand its operational footprint across major regions, including North America, Europe, and Asia, solidifying its market position through strategic partnerships and a robust pipeline of therapeutic solutions.
DitchCarbon Score
How does Kyowa Kirin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kyowa Kirin's score of 62 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kyowa Kirin's reported carbon emissions
In 2023, Kyowa Kirin reported total greenhouse gas emissions of approximately 81,944,000 kg CO2e, comprising 20,336,000 kg CO2e from Scope 1, 16,362,000 kg CO2e from Scope 2, and 45,246,000 kg CO2e from Scope 3 emissions. This reflects a commitment to transparency in emissions reporting across all scopes. The company has set ambitious targets to reduce its greenhouse gas emissions. Specifically, Kyowa Kirin aims to achieve a 42% reduction in Scope 1 and Scope 2 emissions by 2030, using 2021 as the baseline year. This target has been validated by the Science Based Targets initiative (SBTi) and aligns with the goal of limiting global warming to 1.5°C. In 2022, Kyowa Kirin's emissions were approximately 83,818,000 kg CO2e, with Scope 1 emissions at 30,162,000 kg CO2e, Scope 2 at 16,221,000 kg CO2e, and Scope 3 at 83,818,000 kg CO2e. The company has demonstrated a proactive approach to measuring and managing its carbon footprint, including efforts to address Scope 3 emissions, which are often the most challenging to control. Overall, Kyowa Kirin's commitment to reducing its carbon emissions reflects a broader industry trend towards sustainability and environmental responsibility, positioning the company as a leader in climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 18,262,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,740,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kyowa Kirin is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
